The overall goal of the Center for the Study of Inflammatory Bowel Disease (CSIBD) is to promote and facilitate research that will yield insight into the causes and pathogenesis of IBD and lead to improved therapeutic approaches. This overarching objective remains unchanged since the inception of the CSIBD in 1991 and has guided the Center through substantial growth and expansion. The research base is made up of 111 scientists with $48.7 million in digestive disease-related research support. Organizing these investigators by areas of focus, we divide the CSIBD into six central themes. Our goal of understanding human IBD is accomplished using six entry points: (1) genetics, (2) microbial interactions, (3) barrier function and epithelial cell biology, (4) innate and adaptive immunity, (5) therapeutics, and (6) systems biology and signal transduction. Clinicians, scientists, and engineers are embedded in each theme. A central priority of the CSIBD is to bring together researchers from these various approaches and to provide an intellectual nexus for these individuals to find common interests in understanding and treating IBD. This is accomplished through several routes. First, the five biomedical cores offer state-of-the-art resources and expertise from leaders in (1) Human Genetics and Microbiome, (2) Immunology, (3) Morphology, and (4) Genetic Animal Models. In addition to offering guidance and access to technologies, core directors serve as connection points between investigators, facilitating collaborations. Similarly, the (5) Clinical Core aids the community through access to thousands of patient samples while serving as a hub for interactions between clinicians and basic researchers. Operating independently of these cores, the close relationship between the CSIBD and the Broad Institute allows further access to cutting-edge technologies. The overall specific aims of the CSIBD are to (1) promote research in basic science areas relevant to better understanding of mucosal immune function and epithelial biology in IBD; (2) advance our understanding of gut pathophysiology by examining the gut as a circuit: studying the core components of gut intra- and inter-cellular interactions that determine health and disease; (3) promote the study of the pathogenesis of IBD; (4) promote interactions among scientists exploring diverse fields that share relevance to IBD; (5) promote translational IBD research; (6) attract basic investigators to the study of IBD and mucosal immunology; and (7) provide an environment and mechanism to foster development of young investigators focused on IBD. A comprehensive Enrichment Program introduces new members to the IBD community and encourages face-to-face interactions between investigators from a range of fields. Attracting new members to the CSIBD and IBD research is also greatly facilitated through Pilot and Feasibility Program support, the success of which is reflected by 79% of recipients achieving external funding.
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are debilitating conditions that affect more than a million people n the United States. This proposal describes our multi-institutional interdisciplinary center focused on IBD research and its potential to accelerate research in the field of IBD. This research will enable the development of advances in treatment, diagnosis, and prevention of these diseases.
|Gevers, Dirk; Kugathasan, Subra; Knights, Dan et al. (2017) A Microbiome Foundation for the Study of Crohn's Disease. Cell Host Microbe 21:301-304|
|Molinie, Benoit; Giallourakis, Cosmas C (2017) Genome-Wide Location Analyses of N6-Methyladenosine Modifications (m6A-Seq). Methods Mol Biol 1562:45-53|
|Schwerd, Tobias; Pandey, Sumeet; Yang, Huei-Ting et al. (2017) Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut 66:1060-1073|
|Maehara, Takashi; Mattoo, Hamid; Ohta, Miho et al. (2017) Lesional CD4+ IFN-?+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Ann Rheum Dis 76:377-385|
|Jung, Keehoon; Heishi, Takahiro; Khan, Omar F et al. (2017) Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest 127:3039-3051|
|Rooks, Michelle G; Veiga, Patrick; Reeves, Analise Z et al. (2017) QseC inhibition as an antivirulence approach for colitis-associated bacteria. Proc Natl Acad Sci U S A 114:142-147|
|Ananthakrishnan, A N; Sakuraba, A; Barnes, E L et al. (2017) The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Aliment Pharmacol Ther 46:162-168|
|Miyabe, Chie; Miyabe, Yoshishige; Strle, Klemen et al. (2017) An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 76:898-905|
|Ananthakrishnan, Ashwin N; Luo, Chengwei; Yajnik, Vijay et al. (2017) Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 21:603-610.e3|
|Canali, Susanna; Zumbrennen-Bullough, Kimberly B; Core, Amanda B et al. (2017) Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood 129:405-414|
Showing the most recent 10 out of 1056 publications